Allos Therapeutics to Present at Upcoming Investor Conferences
13 Fevereiro 2007 - 11:00AM
PR Newswire (US)
WESTMINSTER, Colo., Feb. 13 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced that the Company's
management will participate in the following upcoming investor
conferences: * Roth Capital Partners 2007 OC Conference --
management will provide a 30 minute corporate overview on
Wednesday, February 21, at 7 PM ET. * Cowen and Company 27th Annual
Healthcare Conference -- management will provide a 35 minute
corporate overview on Monday, March 12, at 1:40 PM ET. Live and
archived web casts of these presentations will be available on the
Company's website: http://www.allos.com/. About Allos Therapeutics,
Inc. Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company
focused on the development and commercialization of small molecule
therapeutics for the treatment of cancer. The Company has two
product candidates in late-stage clinical development: EFAPROXYN
(efaproxiral), a radiation sensitizer currently under evaluation in
a pivotal Phase 3 trial in women with brain metastases originating
from breast cancer, and PDX (pralatrexate), a novel, next
generation antifolate currently under evaluation in a pivotal Phase
2 trial in patients with relapsed or refractory peripheral T-cell
lymphoma. The Company is also evaluating RH1, a targeted
chemotherapeutic agent, in a Phase 1 trial in patients with
advanced solid tumors. For additional information, please visit the
Company's website at http://www.allos.com/ Safe Harbor Statement
The anticipated presentations will contain forward-looking
statements that involve significant risks and uncertainties,
including those to be discussed in the presentations and others
that can be found in the "Risk Factors" section of the Company's
Form 10-K for the year ended December 31, 2005 and in the Company's
periodic reports on Form 10-Q and Form 8-K. The Company does not
undertake any obligation to update any forward-looking statements
contained in the anticipated presentations as a result of new
information, future events or otherwise. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in the presentation. No forward-looking
statement can be guaranteed and actual events and results may
differ materially from those projected. DATASOURCE: Allos
Therapeutics, Inc. CONTACT: Jennifer Neiman, Manager, Corporate
Communications of Allos Therapeutics, Inc., +1-720-540-5227, Web
site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics (MM)